BG108181A - Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7 - Google Patents

Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7

Info

Publication number
BG108181A
BG108181A BG108181A BG10818103A BG108181A BG 108181 A BG108181 A BG 108181A BG 108181 A BG108181 A BG 108181A BG 10818103 A BG10818103 A BG 10818103A BG 108181 A BG108181 A BG 108181A
Authority
BG
Bulgaria
Prior art keywords
phosphodiesterase
inhibitors
novel
spirotricyclic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BG108181A
Other languages
English (en)
Inventor
Patrick Bernardelli
Pierre Ducrot
Edwige Lorthiois
Fabrice Vergne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner-Lambert Co
Original Assignee
Warner-Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG108181(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Co filed Critical Warner-Lambert Co
Publication of BG108181A publication Critical patent/BG108181A/bg
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BG108181A 2001-03-21 2003-09-17 Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7 Pending BG108181A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2001/003355 WO2002076953A1 (en) 2001-03-21 2001-03-21 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
PCT/EP2002/003594 WO2002074754A1 (en) 2001-03-21 2002-03-18 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
BG108181A true BG108181A (bg) 2004-09-30

Family

ID=8164349

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108181A Pending BG108181A (bg) 2001-03-21 2003-09-17 Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7

Country Status (47)

Country Link
US (3) US20020198198A1 (bg)
EP (2) EP1801106A3 (bg)
JP (1) JP4086663B2 (bg)
KR (1) KR100617435B1 (bg)
CN (1) CN100447136C (bg)
AP (1) AP1699A (bg)
AR (1) AR033617A1 (bg)
AT (1) ATE367381T1 (bg)
AU (1) AU2002304800B2 (bg)
BG (1) BG108181A (bg)
BR (1) BR0208192A (bg)
CA (1) CA2441313C (bg)
CU (1) CU23218A3 (bg)
CY (1) CY1106829T1 (bg)
CZ (1) CZ20032451A3 (bg)
DE (1) DE60221233T2 (bg)
DK (1) DK1373224T3 (bg)
EA (1) EA006815B1 (bg)
EC (1) ECSP034750A (bg)
EE (1) EE200300459A (bg)
ES (1) ES2288552T3 (bg)
GE (1) GEP20053631B (bg)
GT (1) GT200200053A (bg)
HK (1) HK1061854A1 (bg)
HR (1) HRP20030740A2 (bg)
HU (1) HUP0303637A3 (bg)
IL (2) IL157659A0 (bg)
IS (1) IS2529B (bg)
MA (1) MA27001A1 (bg)
MX (1) MXPA03008485A (bg)
MY (1) MY142045A (bg)
NO (1) NO326086B1 (bg)
NZ (1) NZ527847A (bg)
OA (1) OA12454A (bg)
PA (1) PA8541601A1 (bg)
PE (1) PE20021010A1 (bg)
PL (1) PL367058A1 (bg)
PT (1) PT1373224E (bg)
RS (1) RS50429B (bg)
SI (1) SI1373224T1 (bg)
SK (1) SK11562003A3 (bg)
SV (1) SV2003000925A (bg)
TN (1) TNSN03076A1 (bg)
TW (1) TWI267509B (bg)
UA (1) UA74243C2 (bg)
WO (2) WO2002076953A1 (bg)
ZA (1) ZA200306601B (bg)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
GB0230195D0 (en) * 2002-12-24 2003-02-05 Biofocus Plc Compound Libraries
PT1622569E (pt) 2003-04-24 2016-03-03 Incyte Corp Derivados de aza espiro alcanos como inibidores de metaloproteases
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
CA2535249A1 (en) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
DK2433943T3 (da) 2004-07-01 2013-12-16 Daiichi Sankyo Co Ltd Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet
GB0504209D0 (en) * 2005-03-01 2005-04-06 Pfizer Ltd New use of PDE7 inhibitors
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AU2006219643A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of PDE7 inhibitors for the treatment of neuropathic pain
KR100680497B1 (ko) * 2005-07-25 2007-02-08 엘지전자 주식회사 근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
EP1957467A2 (en) 2005-12-02 2008-08-20 Pfizer Limited Spirocyclic derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
BRPI0809244A2 (pt) * 2007-03-27 2014-09-23 Omeros Corp Métodos de tratamento de uma anormalidade de movimento, e para identificação de um agente que inibe a atividade pde7.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
EP2160381A2 (en) * 2007-05-24 2010-03-10 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
AU2011326173B2 (en) 2010-11-08 2015-08-27 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG11201508328PA (en) 2013-04-19 2015-11-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107438607B (zh) 2015-02-20 2021-02-05 因赛特公司 作为fgfr抑制剂的双环杂环
CN108602815B (zh) * 2015-12-16 2020-07-28 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107382976A (zh) * 2017-07-04 2017-11-24 孙秀芹 一种治疗盆腔炎的化合物及制备方法和应用
EP3652180B1 (en) * 2017-07-12 2023-11-29 Dart NeuroScience, LLC Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
AU2019262195B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Fgfr阻害剤としての二環式複素環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815979A (ja) 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体およびその製造法
US4764512A (en) 1986-08-27 1988-08-16 Rorer Pharmaceutical Corporation Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
SK282166B6 (sk) 1992-12-11 2001-11-06 Merck & Co., Inc. Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
US5578593A (en) * 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5602143A (en) * 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
BR9610988A (pt) * 1995-10-17 1999-04-06 Astra Pharma Prod Composto uso do mesmo fomulação farmacêutica e processo para produção do composto
CN1205008A (zh) * 1996-08-30 1999-01-13 协和发酵工业株式会社 咪唑并喹唑啉衍生物
SI1173210T1 (en) 1999-05-04 2005-02-28 Wyeth Contraceptive compositions containing antiprogestinic and progestinic
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2000066560A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2001045707A1 (en) 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
EP1373224A1 (en) 2004-01-02
SK11562003A3 (sk) 2005-01-03
CY1106829T1 (el) 2012-05-23
IS6934A (is) 2003-08-29
CN100447136C (zh) 2008-12-31
TWI267509B (en) 2006-12-01
DE60221233T2 (de) 2008-04-03
MY142045A (en) 2010-08-30
KR20030086315A (ko) 2003-11-07
CZ20032451A3 (cs) 2004-09-15
NO20034187D0 (no) 2003-09-19
HUP0303637A3 (en) 2004-07-28
EA006815B1 (ru) 2006-04-28
PA8541601A1 (es) 2003-05-14
HUP0303637A2 (hu) 2004-03-01
ES2288552T3 (es) 2008-01-16
PE20021010A1 (es) 2003-02-01
EP1801106A2 (en) 2007-06-27
AP2003002857A0 (en) 2003-09-30
RS50429B (sr) 2009-12-31
IL157659A (en) 2008-08-07
EP1801106A3 (en) 2007-07-04
DK1373224T3 (da) 2007-10-15
ECSP034750A (es) 2003-10-28
JP4086663B2 (ja) 2008-05-14
KR100617435B1 (ko) 2006-08-31
NO20034187L (no) 2003-10-15
OA12454A (en) 2004-09-30
CU23218A3 (es) 2007-07-20
ATE367381T1 (de) 2007-08-15
TNSN03076A1 (en) 2005-12-23
MA27001A1 (fr) 2004-12-20
US20020198198A1 (en) 2002-12-26
US20070049558A1 (en) 2007-03-01
EP1373224B1 (en) 2007-07-18
WO2002074754A1 (en) 2002-09-26
NO326086B1 (no) 2008-09-15
EA200300906A1 (ru) 2004-02-26
AR033617A1 (es) 2003-12-26
ZA200306601B (en) 2004-08-25
PL367058A1 (en) 2005-02-21
YU74003A (sh) 2006-05-25
IS2529B (is) 2009-07-15
CA2441313C (en) 2009-03-31
US7214676B2 (en) 2007-05-08
GT200200053A (es) 2003-02-12
HK1061854A1 (en) 2004-10-08
US20040214843A1 (en) 2004-10-28
SI1373224T1 (sl) 2007-10-31
GEP20053631B (en) 2005-10-10
CN1498212A (zh) 2004-05-19
JP2004529123A (ja) 2004-09-24
PT1373224E (pt) 2007-09-25
BR0208192A (pt) 2004-03-02
NZ527847A (en) 2005-06-24
DE60221233D1 (de) 2007-08-30
AU2002304800B2 (en) 2007-08-30
HRP20030740A2 (en) 2005-06-30
UA74243C2 (uk) 2005-11-15
IL157659A0 (en) 2004-03-28
WO2002076953A1 (en) 2002-10-03
EE200300459A (et) 2004-02-16
MXPA03008485A (es) 2003-12-08
AP1699A (en) 2006-12-26
SV2003000925A (es) 2003-05-20
CA2441313A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
BG108181A (bg) Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
UA103873C2 (ru) Гетероарильные производные мочевины как ингибиторы р38 и их применение
DE60112974D1 (en) Carbolinderivate
ZA200306419B (en) Phenyl derivatives.
BG106585A (bg) Киназни инхибитори като лекарствени средства
GB0209891D0 (en) Novel compounds
IL174210A0 (en) 1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
GB9801690D0 (en) Therapeutic agents
DE60216233D1 (en) Carbolinderivate
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
MXPA03009750A (es) Compuestos quimicos.
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
SE0302756D0 (sv) Novel Compounds
MXPA02012470A (es) Inhibidores de fosfodiesterasa especificos para gmp ciclico.
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
GB0308201D0 (en) Novel compounds
MXPA03010205A (es) Derivados de acido oxalico.
MXPA03004023A (es) Compuestos quimicos.
MY134079A (en) Derivatives of phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)pheny]-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
MXPA04001121A (es) Derivados de fenilo.
MXPA03011167A (es) Derivados de carbolina utiles como ihibidores de pdev.